PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Terzic, J.* ; Abu El Maaty, M.A. ; Lutzing, R.* ; Vincent, A.* ; El Bizri, R.* ; Jung, M.* ; Keime, C.* ; Metzger, D.*

Hypoxia-inducible factor 1A inhibition overcomes castration resistance of prostate tumors.

EMBO Mol. Med. 15:e17209 (2023)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Androgen deprivation therapy (ADT) is a cornerstone of prostate cancer (PCa) management. Although tumors initially regress, many progress to a hormone-independent state termed castration-resistant PCa (CRPC), for which treatment options are limited. We here report that the major luminal cell population in tumors of Pten(i)pe-/- mice, generated by luminal epithelial cell-specific deletion of the tumor suppressor PTEN after puberty, is castration-resistant and that the expression of inflammation and stemness markers is enhanced in persistent luminal cells. In addition, hypoxia-inducible factor 1 (HIF1) signaling, which we have previously demonstrated to be induced in luminal cells of Pten(i)pe-/- mice and to promote malignant progression, is further activated. Importantly, we show that genetic and pharmacological inhibition of HIF1A sensitizes Pten-deficient prostatic tumors to castration and provides durable therapeutic responses. Furthermore, HIF1A inhibition induces apoptotic signaling in human CRPC cell lines. Therefore, our data demonstrate that HIF1A in prostatic tumor cells is a critical factor that enables their survival after ADT, and identify it as a target for CRPC management.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
11.100
0.000
1
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Hif1a ; Pten ; Castration-resistant Prostate Cancer ; Genetically-engineered Mice ; Single-cell Rna Sequencing; Cancer; Pten; Plasticity; Px-478; Cells
Language english
Publication Year 2023
HGF-reported in Year 2023
ISSN (print) / ISBN 1757-4676
e-ISSN 1757-4684
Journal EMBO Molecular Medicine
Quellenangaben Volume: 15, Issue: 6, Pages: , Article Number: e17209 Supplement: ,
Publisher Wiley
Publishing Place Chichester
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes and Cancer (IDC)
POF-Topic(s) 90000 - German Center for Diabetes Research
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-501900-253
Grants Centre National de la Recherche Scientifique (CNRS)
Institut National de la Sante et de la Recherche Medicale (INSERM)
Universite de Strasbourg
Interdisciplinary Thematic Institute IMCBio, as part of the ITI 2021-2028 program of the University of Strasbourg
CNRS
Inserm
IdEx Unistra
SFRI-STRAT'US project
EUR IMCBio
France Genomique consortium
ITMO Cancer within the funds of the Cancer Plan 2014-2019
French National Cancer Institute
INCa-PLBIO
Fondation ARC pour la Recherche sur le Cancer
Agence Nationale de la Recherche
ITMO Cancer Aviesan/Inserm/Cancer 2020 through the "Formation a la recherche fondamentale et translationnelle en cancerologie" program
Al Bizri Foundation
Agence Nationale de la Recherche (ANR)
Fondation pour la Recherche Medicale grant
DOI 10.15252/emmm.202217209
WOS ID 000974202900001
Scopus ID 85152933338
PubMed ID 37070472
Erfassungsdatum 2023-10-06
[➜Report correction]